Pharmazz
| Industry | Pharmaceutical |
|---|---|
| Founded | 2010 |
| Headquarters | , US |
Area served | Worldwide |
Key people | Anil Gulati (CEO)[1] |
| Subsidiaries | Pharmazz India Private Limited, Pharmazz UK Limited |
| Website | www |
Pharmazz Inc. is an American biopharmaceutical company headquartered in Willowbrook, Illinois.
History[edit]
Pharmazz Inc. was founded in 2010 in Willowbrook, Illinois, US. The company expanded its operations by establishing subsidiaries in India (Pharmazz India Private Limited) and the UK (Pharmazz UK Limited).[2][3] Furthermore, strategic licensing agreements were inked with Midwestern University in 2011[4] and The Board of Trustees of the University of Illinois in 2014.[2]
Clinical development of centhaquine, intended for treatment of hypovolemic shock, commenced in India. It achieved approval for phase I clinical trials in September 2014, followed by phase II in December 2016, and phase III in December 2018. Market authorization was granted in May 2020, with the subsequent launch of Lyfaquin in November 2020, marking a significant milestone.[5]
In September 2023, Sun Pharma partnered with Pharmazz Inc. to introduce sovateltide, an ischemic stroke drug, in India.[6][7] In March 2024, Dr. Reddy's Laboratories partnered with Pharmazz Inc. to bring life-saving Centhaquine (Lyfaquin) to India.[8][9]
Notable publications[edit]
- Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke, 2021, vol:35, Anil Gulati, Nilesh Agrawal, Deepti Vibha, U. K. Misra, Birinder Paul, Dinesh Jain, Jeyaraj Pandian & Rupam Borgohain[10]
- A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients, June 2021, Vol:81, citations:6, Anil Gulati, Rajat Choudhuri, Ajay Gupta, Saurabh Singh, S. K. Noushad Ali, Gursaran Kaur Sidhu, Parvez David Haque, Prashant Rahate, Aditya R. Bothra, Gyan P. Singh, Sanjiv Maheshwari, Deepak Jeswani, Sameer Haveri, Apurva Agarwal & Nilesh Radheshyam Agrawal[11]
References[edit]
- ^ Datta, PT Jyothi (18 April 2024). "Pharmazz scouting for US partners for drugs researched in India". BusinessLine.
- ^ a b P, Anuradha. "Pharmazz Inc.: A Rising Star in Critical Care Medicine". Bru Times News.
- ^ "Pharmazz India Pvt. Ltd shared their research on life saving drugs. - The Pharma Times | Pharma & Health Care News Portal". thepharmatimes.in.
- ^ "Sovateltide - Midwestern University/Pharmazz - AdisInsight". adisinsight.springer.com.
- ^ "Centhaquine set to enter US-FDA approved Phase 3 clinical trial in US and Europe". Express Pharma. 2 August 2023.
- ^ "Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing ischemic stroke drug in India". Financialexpress. 14 September 2023.
- ^ "FDA clears Pharmazz's IND for acute cerebral ischaemic stroke therapy trial". Clinical Trials Arena. 14 February 2023.
- ^ Pilla, Viswanath (22 March 2024). "Dr Reddy's enters licensing pact to market Pharmazz novel therapy Centhaquine in India". The Economic Times.
- ^ "Dr. Reddy's to market U.S. firm Pharmazz's hypovolemic shock drug in India". The Hindu. 22 March 2024.
- ^ Gulati, Anil; Agrawal, Nilesh; Vibha, Deepti; Misra, U. K.; Paul, Birinder; Jain, Dinesh; Pandian, Jeyaraj; Borgohain, Rupam (1 January 2021). "Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke". CNS Drugs. pp. 85–104. doi:10.1007/s40263-020-00783-9.
- ^ Gulati, Anil; Choudhuri, Rajat; Gupta, Ajay; Singh, Saurabh; Noushad Ali, S. K.; Sidhu, Gursaran Kaur; Haque, Parvez David; Rahate, Prashant; Bothra, Aditya R.; Singh, G. P.; Maheshwari, Sanjeev; Jeswani, Deepak; Haveri, Sameer; Agarwal, Apurva; Agrawal, Nilesh Radheshyam (9 May 2021). "A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin ® ) as a resuscitative agent in hypovolemic shock patients". medRxiv: The Preprint Server for Health Sciences. pp. 2020.07.30.20068114. doi:10.1101/2020.07.30.20068114.